menu
    • menu
    [{"orgOrder":0,"company":"Immunome","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Immunome \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"Immunome \/ J.P. Morgan"},{"orgOrder":0,"company":"Immunome","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Immunome \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"Immunome \/ J.P. Morgan"},{"orgOrder":0,"company":"Immunome","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immunome","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Immunome \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"Immunome \/ J.P. Morgan"}]

    Find Clinical Drug Pipeline Developments & Deals for Varegacestat

    Menu

    Varegacestat

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Immunome

                            U.S.A arrow
                            Food Ingredients China
                            Not Confirmed

                            Immunome

                            U.S.A arrow
                            Food Ingredients China
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varegacestat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $172.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Immunome Closes Upsized Public Offering, Underwriters’ Option Fully Exercised

                            Details : The proceeds will fund the clinical and preclinical development of pipeline assets, including AL102 (varegacestat), a gamma secretase and pan-Notch inhibitor, with potential antineoplastic activity.

                            Product Name : AL102

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 31, 2025

                            Lead Product(s) : Varegacestat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $172.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Immunome

                            U.S.A arrow
                            Battery Seminar
                            Not Confirmed

                            Immunome

                            U.S.A arrow
                            Battery Seminar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varegacestat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Immunome Announces Pricing of Upsized Public Offering of Common Stock

                            Details : The proceeds will fund the clinical and preclinical development of pipeline assets, including AL102 (varegacestat), a gamma secretase and pan-Notch inhibitor, with potential antineoplastic activity.

                            Product Name : AL102

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 29, 2025

                            Lead Product(s) : Varegacestat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Immunome

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            Immunome

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varegacestat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Immunome Announces Proposed Public Offering of Common Stock

                            Details : The proceeds will fund the clinical and preclinical development of pipeline assets, including AL102 (varegacestat), a gamma secretase and pan-Notch inhibitor, with potential antineoplastic activity.

                            Product Name : AL102

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 29, 2025

                            Lead Product(s) : Varegacestat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth